NASDAQ
MNOV
Last Price
US $1.31
KEY FIGURES
MKT CAP
$64.5M
EPS
TTM
$-47.19
EPS Growth (1Y)
4.35%
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
0.14x
YIELD
-
GROWTH (5Y CAGR)
Revenue
Valuation
Financial
Performance
Cash flow to debt coverage
MediciNova, Inc. cash flow to debt ratio of -5.05K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
MediciNova, Inc.'s free cash flow has increased -7.83% from $-10.64M last year to $-9.81M, signaling increasing performance
Debt-to-equity ratio
MediciNova, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
MediciNova, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials
Net debt to EBITDA
MediciNova, Inc. has a net cash position, so leverage is healthy.
Interest coverage
MediciNova, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
MediciNova, Inc. has insufficient data to evaluate this check.
Current ratio
MediciNova, Inc.'s short-term assets of $30.99M exceed its short-term liabilities of $3.80M
Return on assets
MediciNova, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
MediciNova, Inc.'s return on equity of -27.29%, is lower than 15.00%, indicating bad performance
Earnings quality
MediciNova, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
MediciNova, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
MediciNova, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
MediciNova, Inc. has negative free cash flow, indicating cash burn
Earnings growth
MediciNova, Inc.'s yearly earnings has decreased 8.58% since last year from $-11.05M to $-12.00M, signaling decreasing performance
Revenue growth
MediciNova, Inc.'s yearly revenue has increased % since last year from $0.00 to $409.66K, signaling increasing performance
Return on invested capital
ROIC -32.47% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
MediciNova, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
MediciNova, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance
Return on equity consistency
MediciNova, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
MediciNova, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
MediciNova, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
MediciNova, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
MediciNova, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
MediciNova, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
MediciNova, Inc. has a price-to-book ratio of 1.65x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
MediciNova, Inc. has a price-to-sales ratio of 109.09x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-24.84%
Return on equity
ROIC: -0.02%
Valuation History
-
Price to Earnings
EV/EBITDA: 2989.8X
Cash flow
Profit margin
-
EBITDA
3.41%
Cash flow
2.06%
Cash Flow (DCF)
Fair Value
Market $1.31
—
Default assumptions
EBITDA Multiple
Fair Value
Market $1.31
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.